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The creation of musculoskeletal tissue represents an alternative for the replacement of soft tissue in reconstructive surgery.
However,mostoftheapproachesofcreatingartiﬁcialtissuehavetheirlimitationsinthesizeasthemaximallyobtainabledimension
of bioartiﬁcial tissue (BAT) is limited due to the lack of supporting vessels within the 3-dimensional construct. The seeded
myoblasts require high amounts of perfusion, oxygen, and nutrients to survive. To achieve this, we developed a 3-dimensional
scaﬀold which features the epigastric artery as macroscopic core vessel inside the BAT in a rat model (perfused group, n = 4) and a
control group (n = 3) without the epigastric vessels and, therefore, without perfusion. The in vivo monitoring of the transplanted
myoblastswasassessedbybioluminescenceimagingandshowedboththeviabilityoftheepigastricarterywithinthe3-dimensional
construct and again that cell survival in vivo is highly depending on the blood supply with the beginning of capillarization within
the BAT seven days after transplantation in the perfused group. However, further studies focussing on the matrix improvement
will be necessary to create a transplantable BAT with the epigastric artery as anastomosable vessel.
1.Introduction
The replacement and reconstruction of musculoskeletal
tissue after severe damage caused by traumatic injury,
tumor surgery, or prolonged denervation is limited with the
utilizable number of transplantable muscle tissue. Moreover,
the transfer of muscle tissue is not uncommonly associated
with aesthetic and functional impairment at the donor site.
Thus, musculoskeletal tissue engineering is attempting to
be an alternative in the challenging ﬁeld of reconstructive
surgery [1–5]. However, during the last decade of stem cell
and tissue engineering research, it turned out that one main
critical factor in tissue engineering is the lack of supporting
bloodvesselsandinsuﬃcientcapillarization[6,7].Therefore
diﬀerent in vivo models like the AV-loop using the femoral
vessels have been developed and conﬁrmed a much higher
cell survival by inducing vascularisation of the used matrix
and furthermore the possibility to create a 3D-bioartiﬁcial
tissue construct [8–14]. In this study, we established a new
in vivo model of musculoskeletal tissue engineering using
the inferior and superior epigastric artery as central-core
vesselsofourcustom-madeimplantablebioreactorchamber.
I no r d e rt of o l l o w - u po u rt r a n s p l a n t e dm y o b l a s t sin vivo,
the cells have been transfected with Luciferase and could in
this way be atraumatically monitored with bioluminescence
[15–17].2 Plastic Surgery International
Figure 1: Immunoﬂuorescence, 200x.2 D - c u l t u r eo fm y o b l a s t s
harvested from5days oldmale Wistar rats:Desmin (green),nucleic
counterstain with DAPI (blue).
2.MaterialsandMethods
2.1. Myoblasts Cell Culture. Myoblasts were harvested by
dissecting the soleus and gastrocnemius muscles of 5 days
old male Wistar rats (Charles River, Kisslegg, Germany) as
described by Bach et al. [12]. Satellite cells were obtained
from the minced muscles by digestion with 0.1% collagenase
type III (Biochrom, Berlin, Germany) for 60 minutes and
0.25% trypsin (Viralex, PAA Laboratories, Linz, Austria)
for 45 minutes at 37◦ Celsius. These cells were ﬁltered and
cell culture was performed in Dulbecco’s modiﬁed Eagle’s
mediumcontaining1%penicillin/streptomycinsolutionand
10% foetal bovine serum (all from FBS, Viralex, PAA
Laboratories, Linz, Austria). Medium was changed every 2
to 3 days and cells were expanded through two passages by
detachment using 0.25% trypsin, followed by resuspension,
collection, and seeding in new culture ﬂasks at a ratio of 1:3.
2.2. Immunoﬂuorescence Staining for Desmin. The myogenic
speciﬁcity of harvested myoblasts was veriﬁed by Desmin-
and MyoD-immunocytochemistry (see Figure 1 (Desmin)
before transplantation and Figure 6 (MyoD) after explan-
tation). Therefore, the cell cultures were ﬁxed in 100%
methanol for 20 minutes at −20◦ Celsius, washed with
(PBS Biochrom, Berlin, Germany), and permeabilized with
TRITON X-100 (Sigma-Aldrich, Irvine, UK) 0.25% in PBS
for 30 minutes. The cultures were then incubated with
blocking solution (5% goat serum and 0.1% TRITON X-100
in PBS) for 30 minutes. After being washed with PBS, the
cultures were incubated with rabbit anti-Desmin polyclonal
antibody (Sigma-Aldrich, Irvine, UK). The cultures were
then washed with PBS and incubated with anti-rabbit,
IgG for 2 hours diluted 1:1500 in blocking solution.
Finally nuclear counterstaining with DAPI (Sigma Aldrich,
Irvine, UK) was performed through incubation with DAPI
10µg / 1m La q u ab i d e s tf o r3 0m i n u t e sa tr o o mt e m p e r a t u r e
followedbywashingsteps.AfterbeingmountedwithMowiol
(Sigma-Aldrich, Irvine, UK), the Desmin-stained cultures
were viewed and photographed by ﬂuorescence microscopy
(Carl Zeiss MicroImaging, Jena, Germany).
2.3. Lentiviral Production and Infection (Luciferase). For the
production of lentivirus, 7 × 106 HEK 293T cells were
Figure 2: Implantation site showing the rectus abdominis dissected
free with the superior and inferior epigastric vascular pedicle along
the deep surface of the muscle. The in vivo bioreactor chamber is
assembled around the epigastric vessels.
seeded onto a 15cm Petri dish and transfected after 24h
with jetPEI (PEQLAB) using 9.4g of transfer vector pEMW-
Luc (containing the coding sequence of Luciferase), 6.1g of
psPAX2 (packaging plasmid), and 3.3g of pMD2. G (VSV-
G envelope). Lentivirus were harvested 48h after trans-
fection, passed through a 0.22µm ﬁlter, and concentrated
by ultracentrifugation at 26000rpm for 2h at 4◦C. Viral
particles were resuspended in PBS and stored at −80◦C.
For infection with the lentiviral stock, primary myoblasts
were seeded in 10-cm plates in complete medium and
infected with viral particles (MOI 5) and 8g/L polybrene
for 16h at 37◦C. Media were changed to growth media
without polybrene. The average percentage of success of the
transfected myoblasts was 89.4 percent in our eﬃcacy tests.
2.4. Surgical Procedure. Male Wistar rats (Charles River,
Kisslegg, Germany) at the age of 4 to 5 weeks served
as recipients of the in vivo bioreactor chamber. German
regulations for the care and use of laboratory animals
have been observed at all times. All experimental protocols
were approved by the governmental review committee of
Northrhine-Westfalia,Germany.Theanimalswerehousedin
the veterinary care facility of the RWTH University Hospital
under temperature-controlled conditions at 21 ± 1◦Cw i t ha
cycle of 12-hour light and 12-hour darkness as well as free
access to standard food and water.
Operations were performed by the same microsurgeon
under an operative microscope (Karl-Zeiss, Jena, Ger-
many). Anesthesia was induced with inhalative Isoﬂurane
(Baxter, Unterschleißheim, Germany) and maintained by
intraperitoneal injection of Ketamine (10%, 0.6mL/kg) and
Medetomidine (0.3mL/kg; Pﬁzer, Paris, France). Ketoprofen
(5mg/kg)wasadministeredpreoperativelyforanalgesia.The
surgical site was shaved, prepped, and draped for sterility. A
mid-line incision was made and perforating branches to thePlastic Surgery International 3
cutaneoustissuewerecauterized.Thedissectionoftherectus
abdominis muscle was performed along the linea alba as
described by Zhang et al. [18] starting retrograde from 2cm
above the symphysis pubis to the xyphoid (see Figure 2).
Furthermore, for the group with perfused BAT (n = 4), the
epigastric artery and vein were dissected carefully from the
rectus abdominis muscle with a total length of at least 3cm.
The lower part of the polyoxymethylene (POM) customized
bioreactor chamber (outer width 10mm, length 20mm,
height 6mm) was positioned under the epigastric vessels
using these vessels as central-core vessels of the in vivo
chamber. Fibrin glue was administered as matrix (Baxter,
Unterschleißheim, Germany) embedding the epigastric ves-
sels in the bioreactor, and 4 × 106 myoblasts were suspended
and mixed with the ﬁbrin glue subsequently to complete
thebioartiﬁcialtissue(seeFigure 3).Thebioreactorchamber
was closed by attaching the upper part. The blood ﬂow of
the epigastric artery was checked by Doppler sonography
proximal and distal of the chamber to ensure the patency
before wound closing. Subsequently, the rectus abdominis
musclewasadaptedusingProlene5-0(Ethicon,Norderstedt,
Germany) to achieve stability of the abdominal wall and
protection of the bioreactor chamber. Finally, the wound was
closed using Vicryl 5-0 (Ethicon, Norderstedt, Germany).
In the control group with unperfused BAT (n = 3),
the bioreactor chamber was implanted as described but
without preparation and use of the epigastric vessels. For
the explantation of the bioreactor chamber, the animals were
reanaesthetized as described before on day seven, and after
exposing the chamber, the epigastric artery was ligated and
transected proximal and distal of the chamber allowing to
remove the bioreactor completely without manipulation.
After this explantation on day seven, the animals were
sacriﬁced by intracardiac potassium chloride injections.
2.5. Bioluminescence Imaging. The followup of the trans-
planted myoblasts inside the in vivo bioreactor chamber
was assessed by means of bioimaging with an ultrasensitive
Xenogen camera (IVIS Lumina, Caliper Life Sciences, MA,
USA) using the reporter D-Luciferin at diﬀerent time
points (d0, d1, d7). The animals were anesthetized with
2% Isoﬂurane and placed in the imaging chamber. After
acquisition of a baseline image, the rats were injected with
the substrate Luciferin intraperitoneally in order to induce
photons (green light emission at 562nm). The region of
interest (ROI) was deﬁned as the site where the in vivo
bioreactor chamber is located. Peak signal (photons/second
[p/s]) from that ﬁxed ROI was evaluated using the Living
Image 2.50 software (Xenogen). The background signal was
evaluated at diﬀerent locations not close to the bioreactor
c h a m b e ra sw e l la sa td i ﬀerent time points (d0, d1, d7) and
subtracted from the corresponding peak signal.
2.6. Immunoﬂuorescence Staining for MyoD (after Explanta-
tion). Cryosections of explanted bioartiﬁcial tissue contain-
ingmyoblastsofd7werewashedwithPBS.Thecultureswere
then incubated with blocking solution (5% goat serum and
0.1% TRITON X-100 in PBS) for 10min. After being washed
∗
5 mm
Figure 3: The implanted in vivo bioreactor chamber (outer
width 10mm, length 20mm, height 6mm) in a 4-weeks-old male
Wistar rat with the epigastric artery (∗) as central-core vessel; the
transplanted and luciferase-transfected myoblasts are embedded in
a ﬁbrinogen matrix.
with PBS, the cultures were incubated with mouse anti-
MyoD monoclonal antibody (Thermo Scientiﬁc, Astmoor,
UK), diluted 1:50 in blocking solution (2h at 20◦C), and
again washed with PBS and incubated with anti-mouse IgG
(KPL, MD, USA) for 2h diluted 1:100 in blocking solution.
After being washed with PBS and mounted with Mowiol,
anti-MyoD-stained cultures were viewed and photographed
by ﬂuorescence microscopy.
3. Results and Discussion
3.1. Myoblasts Can Be Luciferase-Transfected and Therefore
Monitored In Vivo with Bioluminescence. The biolumines-
cence followup monitoring of the Luciferase-transfected
myoblastsshowedtheexpectedresultswithahighnumberof
photons per second on day 0 directly after surgery (1.769 ×
108 photons/sec, see Figure 4 and Table 1) and exponentially
decreasing bioluminescence signals on day 1 and 7 (3.426 ×
107 photons/sec and 3.031 × 106 photons/sec) indicating
the remission of the myoblasts cell survival. The evaluated
background signals (4.822 × 105 photons/sec) showed no
signiﬁcant diﬀerences in terms of location and time points.
However, in unperfused BATs without arterial inﬂow, and
therefore, no possible Luciferin supply, only the background
signals (e.g., 4.110 × 105 photons/sec on day 0) could be
detected as well. Furthermore, the circumstance of retrieving
bioluminescence signals in the perfused BATs (see Figures
4(a)–4(c)) and only background signals in the unperfused
BATs (see Figure 4(d)) was approving the reliable patency of
the epigastric artery as central-core vessel (see ∗ at Figure 5)
insidetheBATbyprovidingtheLuciferin-substrateviablood
ﬂow to the BAT. Therefore, this animal model oﬀers both
an in vivo bioreactor model for musculoskeletal or other
diﬀerent cell types including a central anastomosable core
vesselaswellasthepossibilityofmonitoringthetransplanted
cells, in our study transfected myoblasts in vivo. Thus, the
required animal number can be reduced, as there is no
exceeding animal sacriﬁce necessary at diﬀerent time points.4 Plastic Surgery International
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Figure 4: Bioluminescence followup after myoblasts implantation including the epigastric artery as central-core vessel (perfused BAT): (a)
day of surgery, (b) 1 day after implantation, (c) 7 days after implantation, (d) 7 days after implantation of myoblasts without central-core
vessel in 3D-construct (unperfused BAT).
Table 1: Bioluminescence imaging of the BATs perfused (n = 4)
and unperfused (n = 3) on day 1, 3, and 7 after myoblasts-
transplantation in photons/second and standard deviation (SD).
As no substrate (Luciferin) can reach the transfected myoblasts
within the unperfused BAT inside the bioreactor chamber, only
background signals can be detected.
Perfused BAT Unperfused BAT
photons/sec ±SD
d0 1.769 ×108 ±1.576 ×107 4.110 ×105 ±3.519 ×104
d1 3.426 ×107 ±2.414 ×106 5.172 ×105 ±5.822 ×104
d7 3.031 ×106 ±4.087 ×105 4.652 ×105 ±7.527 ×104
3.2. Capillarization within the Perfused BAT. Pulsatile per-
fusion within a 3-dimensional bioartiﬁcial tissue construct
is promoting the capillarization [8, 9]. In our study, we
could show that the epigastric artery is applicable as central-
core vessel. Nevertheless, we could also show that seven days
after transplantation there was a beginning capillarization
within the BAT, in the areas close to the core vessel (see
< at Figure 5). Further we could also prove the presence of
myoblasts with positive MyoD staining by immunoﬂuores-
cence (see Figure 6) after explantation on day seven showing
thatthemyoblastphenotypepersistedconsistently.However,
improvement of the matrix, for example, by inserting
synthesized polymer ﬁbers to achieve a more muscle-ﬁber-
like structure will be needed to achieve both, a long-time
stability as well as an organized histomorphological patternPlastic Surgery International 5
Figure 5: H&E staining of an explanted perfused BAT seven days
after implantation showing the lumen of the epigastric artery
(∗), myoblasts inside the ﬁbrin matrix (>)a sw e l la ss t a r t i n g
capillarization within the matrix (<).
Figure 6: Immunoﬂuorescence, 400x. Explanted perfused BAT
sevendaysaftertransplantationshowingpositiveMyoDstainingfor
myoblasts.
of the myoblasts to get one more step closer to the use of
bioartiﬁcial tissue in reconstructive surgery.
4. Conclusions
Myoblasts can be transfected with Luciferase and, therefore,
bioluminescence is an eﬀective and reliable method for
assessment of myoblasts cell graft survival in vivo.T h e
implantation of the in vivo bioreactor with the epigastric
artery as core vessel was performed routinely with regular
patency of the vessel and without any side eﬀects or wound
problems during the experimental period. Again, starting
capillarization was found in the areas close to the core
vessel. Thus, the epigastric artery is applicable as central-core
vessel of the 3-dimensional construct and could later be also
used as an anastomosable vessel of artiﬁcial musculoskeletal
tissue for further experimental reconstructive surgeries after
optimizing both matrix and cell survival. However, with the
use of a predeﬁned customized in vivo bioreactor chamber,
this model oﬀers also a variety of possible applications to
create vascularized artiﬁcial tissue.
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